References
- Fenstermaker RA, Ciesielski MJ. Immunotherapeutic strategies for malignant glioma. Cancer Control. 2004;11(3):181–191. doi:https://doi.org/10.1177/107327480401100306.
- Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97–117. doi:https://doi.org/10.1146/annurev.pathol.1.110304.100043.
- Yang MY, Zetler PM, Prins RM, Khan-Farooqi H, Liau LM. Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. Expert Rev Neurother. 2006;6(10):1481–1494. doi:https://doi.org/10.1586/14737175.6.10.1481.
- Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Overview of current immunotherapeutic strategies for glioma. Immunotherapy. 2015;7(10):1073–1104. doi:https://doi.org/10.2217/imt.15.75.
- Acharya S, Chatterjee S, Kumar P, Bhattacharjee M, Chaudhuri S, Chaudhuri S. Induction of G1 arrest in glioma cells by T11TS is associated with upregulation of Cip1/Kip1 and concurrent downregulation of cyclin D (1 and 3)). Anticancer Drugs. 2010;21(1):53–64. doi:https://doi.org/10.1097/CAD.0b013e32833276e8.
- Sarkar S, Begum Z, Dutta S, Chaudhuri S, Chaudhuri S. Sheep form of Leucocyte Function Antigen 3 (TIITS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor: a new approach to biological response modifier therapy. J Exp Clin Cancer Res. 2002;21(1):95–106.
- Chatterjee S, Laskar A, Chatterjee A, Mandal C, Chaudhuri S. In silico structural analysis of an immunotherapeutic glycoprotein T11TS. Int J Biol Med Res. 2011;2(1):346–357.
- Chatterjee S, Acharya S, Kumar P, Chatterjee A, Chaudhuri S, Ghosh A, Chaudhuri S. Comparative evaluation of T11 target structure and its deglycosylated derivative nullifies the importance of glycan moieties in immunotherapeutic efficacy. Acta Biochim Biophys Sin . 2012;44(3):259–268. doi:https://doi.org/10.1093/abbs/gmr120.
- Chaudhuri S, Singh MK, Bhattacharya D, Datta A, Hazra I, Mondal S, et al. T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: clues toward enhanced T-cell survival in rat glioma model. J Cell Physiol. 2018; 233(2):759–770. doi:https://doi.org/10.1002/jcp.26047.
- Ghosh A, Bhattacharjee M, Sarkar P, Acharya S, Chaudhuri S. T11TS exerts effector function by activating immune cells in CNS against glioma where cytokine modulations provide the favourable microenvironment to act. Ind J ExpBiol. 2010;48:879–888.
- Bhattacharjee M, Acharya S, Ghosh A, Sarkar P, Chatterjee S, Kumar P, Chaudhuri S. Bax and Bid act in synergy to bring about T11TS-mediated glioma apoptosis via the release of mitochondrial cytochrome c and subsequent caspase activation. Int Immunol. 2008;20(12):1489–1505. doi:https://doi.org/10.1093/intimm/dxn109.
- Singh MK, Bhattacharya D, Chaudhuri S, Acharya S, Kumar P, Santra P, et al. T11TS inhibits glioma angiogenesis by modulation of MMPs, TIMPs, with related integrin αv and TGF-β1 expressions. Tumour Biol. 2014;35(3):2231–2246. doi:https://doi.org/10.1007/s13277-013-1296-8.
- Bhattacharya D, Singh MK, Chaudhuri S, Acharya S, Basu AK, Chaudhuri S. T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells. J Neurooncol. 2013;113(1):13–25. doi:https://doi.org/10.1007/s11060-013-1095-5.
- Chaudhuri S. An immunomolecular therapy of brain tumors with T11TS/SLFA-3: from bench towards bedside. In: Talwar GP, Sood OP, editors. Immunotherapeutic & disease management: recent advances. Haryana, India: Ranbaxy Science Foundation; 2007. p. 69–79.
- Mukherjee J, Ghosh A, Sarkar P, Mazumdar M, Banerjee C, Chaudhuri S. Immunotherapy with T11TS/S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status. Anticancer Res. 2005;25:2905–2920.
- Bhattacharya D, Chaudhuri S, Singh MK, Chaudhuri S. T11TS inhibits angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model. Exp Mol Pathol. 2015;98(3):455–466. doi:https://doi.org/10.1016/j.yexmp.2015.03.026.
- Bulnes S, Bengoetxea H, Ortuzar N, Argandona EG, Garcia-Blanco A, Rico-Barrio I, Lafuente JV. Angiogenic signalling pathways altered in gliomas: selection mechanisms for more aggressive neoplastic subpopulations with invasive phenotype. J Signal Transduct. 2012;2012:597915. doi:https://doi.org/10.1155/2012/597915.
- Kumar P, Chatterjee S, Acharya S, Kumari A, Chaudhuri S, Singh MK, et al. Significant modulation of macrophages associated cytokines TNF-α, VEGF and apoptotoic protein Bax, Bcl2 abrogates tumor cells. Cell Immunol. 2013;284(1–2):172–181. doi:https://doi.org/10.1016/j.cellimm.2013.07.020.
- Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016;45:87–96. doi:https://doi.org/10.1016/j.ctrv.2016.03.004.
- Cho DC. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook. BioDrugs. 2014;28(4):373–381. doi:https://doi.org/10.1007/s40259-014-0090-5.
- Wymann MP, Zvelebil M, Laffargue M. Phosphoinopsitide 3-kinase signaling –which way to target? Trends Pharmacol Sci. 2003;24(7):366–376. doi:https://doi.org/10.1016/S0165-6147(03)00163-9.
- Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15(23):6541–6551. doi:https://doi.org/10.1002/j.1460-2075.1996.tb01045.x.
- Pasku D, Soufla G, Katonis P, Tsarouhas A, Vakis A, Spandidos DA. Akt/PKB isoforms expression in the human lumbar herniated disc: correlation with clinical and MRI findings. Eur Spine J. 2011;20(10):1676–1683. doi:https://doi.org/10.1007/s00586-011-1841-3.
- Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res. 2001;264(1):29–41. doi:https://doi.org/10.1006/excr.2000.5130.
- Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008;27(41):5511–5526. doi:https://doi.org/10.1038/onc.2008.246.
- Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273–291. doi:https://doi.org/10.1038/nrclinonc.2018.28.
- Li W, Du Q, Li X, Zheng X, Lv F, Xi X, et al. Eriodictyol inhibits proliferation, metastasis and induces apoptosis of glioma cells via PI3K/Akt/NF-κB signaling pathway. Front Pharmacol. 2020;11(11):114. doi:https://doi.org/10.3389/fphar.2020.00114.
- Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1(14):1001–1008. PMID: 14707283.
- Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA. PKB/AKT phosphorylation of the transcription factor twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene. 2010;29(24):3554–3565. doi:https://doi.org/10.1038/onc.2010.115.
- Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem. 2002;277(24):21843–21850. doi:https://doi.org/10.1074/jbc.M109745200.
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91(2):231–241. doi:https://doi.org/10.1016/s0092-8674(00)80405-5.
- Mukherjee J, Sarkar S, Begum Z, Dutta S, Ghosh A, Chaudhuri S. Preclinical changes in immunoreactivity and cellular architecture during the progressive development of intracranial neoplasm and its immunotherapeutic schedule with a novel biological response modifier, the T11TS/S-LFA-3. Asia Pac J Can Prev. 2002;3:325–337. PMID: 12716291.
- Mukherjee J, Sarkar S, Ghosh A, Dutta GA, Chaudhuri S, Chaudhuri S. Immunotherapeutic effects of T11TS/S-LFA3 against nitrosocompound mediated neural genotoxicity. Toxicol Lett. 2004;150(3):239–257. doi:https://doi.org/10.1016/j.toxlet.2004.01.016.
- Lenting K, Verhaak R, Laan ter M, Wesseling P, Leenders W. Glioma: experimental models and reality. Acta Neuropathol. 2017;133(2):263–282. doi:https://doi.org/10.1007/s00401-017-1671-4.
- Russell DS, Rubinstein LJ. Experimental tumors of the nervous system. In: Rubinstein LJ, editor. Pathology of tumors of the nervous system. London: Edward Arnold Publication; 1990. p. 58–71.
- Lantos PL, Vanderberg SR, Kleihues P. Tumors of the nervous system. In: Graham D, Lantos PL, editors. Greenfield’s neuropathology. 6th ed. Abingdon: Taylor & Francis; 2000. p. 583–600.
- Kleihues P, Doerjer G, Swenberg JA, Hauenstein E, Bücheler J, Cooper HK. DNA repair as regulatory factor in the organotropy of alkylating carcinogens. Arch Toxicol Suppl. 1979;2(2):253–261. doi:https://doi.org/10.1007/978-3-642-67265-1_21.
- Kleihues P, Meer I, Wrestler OD, Bamberg M. Formation and repair of O-alkylated DNA bases: role in neurocarcinogenesis and chemotherapy. In: Grundmann E, editor. Cancer campaign, experimental neurooncology, brain tumor and pain therapy. Vol. 10. Stuttgart, York: Gustav Fischer; 1987. p. 1–17.
- Briançon-Marjollet A, Balenci L, Fernandez M, Estève F, Honnorat J, Farion R, et al. NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N-ethyl-N-nitrosourea-induced gliomagenesis. Carcinogenesis. 2010;31(10):1718–1725. doi:https://doi.org/10.1093/carcin/bgq154.
- Mukherjee J, Ghosh A, Ghosh A, Chaudhuri S. ENU administration causes genomic instability along with single nucleotide polymorphisms in p53 during gliomagenesis: T11TS administration demonstrated in vivo apoptosis of these genetically altered tumor cells. Cancer Biol Ther. 2006;5(2):156–164. doi:https://doi.org/10.4161/cbt.5.2.2313.
- Zook BC, Simmens SJ, Jones RV. Evaluation of ENU-induced gliomas in rats: nomenclature, immunochemistry, and malignancy. Toxicol Pathol. 2000;28(1):193–201. doi:https://doi.org/10.1177/019262330002800124.
- Reifenberger G, Bilzer T, Seitz RJ, Wechsler W. Expression of vimentin and glial fibrillary acidic protein in ethylnitrosourea-induced rat gliomas and glioma cell lines. Acta Neuropathol. 1989;78(3):270–282. doi:https://doi.org/10.1007/BF00687757.
- Colello RJ, Sato-Bigbee C. Purification of oligodendrocytes and their progenitors using immunomagnetic separation and percoll gradient centrifugation. Curr Protoc Neurosci. 2001;3:3–12. doi:https://doi.org/10.1002/0471142301.ns0312s03.
- Weinstein DE. Isolation and purification of primary rodent astrocytes. Curr Protoc Neurosci. 2001;3:3–5. doi:https://doi.org/10.1002/0471142301.ns0305s00.
- Scheid MP, Woodgett JR. Protein kinases: six degrees of separation? Curr Biol. 2000;10(5):R191–R194. doi:https://doi.org/10.1016/s0960-9822(00)00349-3.
- Ghosh A, Mukherjee J, Bhattacharjee M, Sarkar P, Acharya S, Chaudhuri S. T11TS/SLFA-3 differentially regulate the population of microglia and brain infiltrating lymphocytes to reduce glioma by modulating intrinsic Bcl-2 expression rather than p53. CNSAMC. 2007;7(2):145–155. doi:https://doi.org/10.2174/187152407780831684.
- Singh MK, Chaudhuri S, Bhattacharya D, Kumar P, Datta A, Chaudhuri S. T11 Target Structure induced modulations of the pro-inflammatory and anti-infammatorycytokine expressions in experimental animals for glioma abrogation. Int Immunopharmacol. 2015;24(2):198–207. doi:https://doi.org/10.1016/j.intimp.2014.12.010.
- Rasheed BA, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Research. 1997;57(19):4187–4190.
- Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol. 2003;15(3):197–203. doi:https://doi.org/10.1097/00001622-200305000-00003.
- Davis MA, LuY Sano T, Fang X, Tang P, LaPushin R, Koul D, et al. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibiots Akt activation and induces anoikis. Cancer Res. 1998;58:5285–5290.
- Kreis NN, Louwen F, Yuan J. Less understood issues: p21(Cip1) in mitosis and its therapeutic potential. Oncogene. 2015; 34(14):1758–1767. doi:https://doi.org/10.1038/onc.2014.133.
- Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55(1):96–107. doi:https://doi.org/10.1007/s000180050273.
- Juven-Gershon T, Oren M. Mdm2: the ups and downs. Mol Med. 1999;5(2):71–83. PMID: 10203572. doi:https://doi.org/10.1007/BF03402141.
- Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem. 1999;274(51):36031–36034. doi:https://doi.org/10.1074/jbc.274.51.36031.
- Alarcon-Vargas D, Ronai Z. p53-MDM2-the affair that never ends. Carcinogenesis. 2002;23(4):541–547. doi:https://doi.org/10.1093/carcin/23.4.541.
- Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010;24(15):1580–1589. doi:https://doi.org/10.1101/gad.1941710.
- Sarkar S, Ghosh A, Mukherjee J, Chaudhuri S, Chaudhuri S. CD2-SLFA3/T11TS interaction facilitates immune activation and glioma regression by apoptosis. Cancer Biol Ther. 2004;3(11):1121–1128. doi:https://doi.org/10.4161/cbt.3.11.1214.
- Begum Z, Ghosh A, Sarkar S, Mukherjee J, Mazumdar M, Sarkar P, Chaudhuri S. Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/SLFA-3. Glycoconj J. 2004;20(9):515–523. doi:https://doi.org/10.1023/B:GLYC.0000043287.98081.15.
- Ghosh A, Mukherjee J, Bhattacharjee M, Sarkar P, Acharya S, Chaudhuri S, Chaudhuri S. The other side of the coin: beneficiary effect of ‘oxidative burst’ upsurge with T11TS facilitates the elimination of glioma cells. Cell Mol Biol 2007;53(5):53–62. PMID: 17543233.
- Sarkar P, Bhattacharjee M, Acharya S, Ghosh A, Chaudhuri S. Functional and receptor modulations of T lymphocytes and macrophage in acute and subacute dose finding studies of a novel immunotherapeutic molecule T11TS. J Cell Tissue Res. 2007;7(2):1013–1018.